N6022 exerted a rapid onset of action in OVA-sensitized mice. OVA-sensitized mice were treated with a single i.v. dose of N6022 administered 30 min to 8 h prior to MCh challenge. PBS vehicle was given as a single i.v. dose 8 h prior to MCh challenge. IpBr + Alb was administered as inhaled doses at 48 h, 24 h, and 1 h prior to MCh as a positive control for the model. Penh was measured at baseline and after challenge with saline followed by increasing doses of MCh aerosol. BALF eosinophils were quantified via light microscopy. Plasma RANTES was measured via enzyme immunoassay. N6022 attenuated Penh (A), BALF eosinophils (B), and plasma RANTES (C) in OVA-sensitized mice starting as early as 30 minutes with more pronounced effects occurring at 8 h. Bars are the means ± SEM of 10 mice per group for (A) and (B), and 4 mice per group for (C). *p < 0.05 for treatment vs. vehicle, One-way ANOVA, Dunnett’s.